By: IPP Bureau
Last updated : August 03, 2021 7:04 pm
2DG has been given emergency approval by the Drug Controller General of India (DCGI) for use on COVID-19 patients in the country
Laurus Labs Limited, a leading research & development-driven and fully integrated pharmaceutical and biotech company in India, has received the licence from Defence Research & Development Organisation (DRDO) to manufacture and market 2-Deoxy-D-Glucose (2DG).
2DG has been given emergency approval by the Drug Controller General of India (DCGI) for use on COVID-19 patients in the country.
Laurus Labs has already applied with CDSCO for emergency use authorization (EUA) for 2DG.
Laurus Labs has grown to become one of the leading manufacturers of API for Anti-Retroviral (ARV), Oncology, Cardiovascular, Anti-Diabetics, Anti-Asthma, and Gastroenterology. The company is thriving on growth opportunities in formulation manufacturing to service all leading markets of North America, Europe, and Low Middle-Income Countries (LMIC). We are driving growth opportunities in Contract Development and Manufacturing through our Synthesis business.